The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
191
0.9% Normal Saline
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Rate of major, clinically important non-major or minor bleeding
Time frame: 26 weeks
Clotting in extracorporeal dialysis circuit
Time frame: During Hemodialysis (weekly for 26 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
0.9% Normal Saline